BACKGROUND: Artificial intelligence (AI) application is increasingly used in all fields, especially, in medicine. However, for the successful incorporation of AI-driven tools into medicine, healthcare professional should be equipped with the necessary knowledge. From that, we aimed to assess the AI readiness among medical students in Jordan. METHODS: A cross-sectional survey was conducted among medical students across 6 Jordanian universities. Prevalidated Medical Artificial Intelligence Readiness Scale for Medical Students questionnaire was used. The questionnaire was distributed through social media groups of students. SPSS v.27 was used for analysis. RESULTS: A total of 858 responses were collected. The mean AI readiness score was 64.2%. Students scored more in the ability domain with a mean of 22.57. We found that academic performance (Grade point average) positively associated with overall AI readiness ( P = .023), and prior exposure to AI through formal education or experience significantly enhances readiness ( P = .009). In contrast, AI readiness levels did not significantly vary across different medical schools in Jordan. Notably, most students (84%) did not receive a formal education about AI from their schools. CONCLUSION: Incorporation of AI education in medical curricula is crucial to close knowledge gaps and ensure that students are prepared for the use of AI in their future career. Our findings highlight the importance of preparing students to engage with AI technologies, and to be equipped with the necessary knowledge about its aspect.

BACKGROUND: Low quality of life (QoL) in university students is often associated with unhealthy lifestyle and negative impacts on students’ ability to learn and succeed. To date, no research has examined the QoL of medical students in Jordan or the demographic factors that may associate with lower QoL. MATERIALS AND METHODS: A quantitative, cross-sectional study with a descriptive design was chosen for this study. Participants were 512 medical students from one public university in Jordan. The Arabic version of the World Health Quality of life-brief survey (WHOQOL-BREF) was used to collect data online from students. RESULTS: Regarding the overall QoL, most students rated their QoL (67%) and health satisfaction (64%) as good. There were significant differences across the various QoL domains in relation to gender, academic achievements, and academic year level (P < 0.005). The physical health domain had the highest mean score (60.60 ± 17.00), while psychological health domain had the lowest mean score (56.90 ± 17.75). CONCLUSION: Lower QoL scores among female students may reflect a socially disadvantaged environment and poorer well-being for female medical students. Lower scores in physical and psychological domains among students with lower GPAs suggest the need for initiating well-being programs to promote a study-friendly atmosphere.

Background: Astrocytoma is a primary brain tumor arising from specific glial cells called astrocytes. Isocitrate dehydrogenase (IDH) mutations represent an early oncogenic event in glioma evolution. The 2-hydroxyglutarate builds up and is produced in grade II/III astrocytoma. Adjuvant chemo(radio)therapy is the standard treatment. Optimal treatment strategies are controversial due to the risk-benefit ratio. This study aimed to assess the effect of IDH mutation on the survival outcome with different treatment modalities for better understanding of the disease. Methods: Data were obtained from the SEER program for patients with diffuse and anaplastic astrocytoma diagnosed from 2018 to 2020. Patients were divided into wild-type (wIDH) and mutant-type (mIDH) groups and subclassified based on the received adjuvant therapy (chemotherapy, radiotherapy, chemoradiotherapy). All patients had surgery (tumor destruction, local excision, partial, radial, and total gross resection). SPSS 27 was used for statistical analysis, Kaplan–Meier curve, and Long-Rank test for survival analysis. Results: Out of 811 patients, 486 (59.9%) had mIDH, and 325 (40.1%) had wIDH. The 2-year relative survival for mIDH was 95% and 51% for wIDH, P < 0.001. The highest 2-year relative survival among the mIDH group was for patients who received adjuvant chemotherapy (100%), compared to adjuvant chemoradiotherapy (95.3%) and adjuvant radiotherapy (81.2%), P = 0.051. The 2-year survival for wIDH who received adjuvant chemotherapy, combined adjuvant chemoradiotherapy, and adjuvant radiotherapy were 66%, 51%, and 42%, respectively; P = 0.022. Conclusions: The mIDH had better 2-year relative survival compared to wIDH across all treatment modalities. Adjuvant chemotherapy had more than 20% survival benefit compared to radiotherapy in mIDH and wIDH. These results highlight adjuvant chemotherapy as the modality of choice for mIDH to improve the survival outcome and avoid radiotherapy’s unfavorable side effects. The study was registered at Clinicaltrial.gov with identification number of NCT06620926.

Background: Adjuvant radiation therapy for breast cancer improves survival but may expose thoracic organs to low-dose radiation, potentially increasing the risk of second primary lung cancer (SPLC). Prior studies have not adequately examined how SPLC risk varies across racial and ethnic groups or whether social factors influence incidence and survival outcomes. Objectives: To quantify racial and ethnic disparities in SPLC incidence and survival among breast cancer survivors treated with radiation and assess the potential protective role of marital status. Methods: We used SEER-17 registry data to identify patients diagnosed with a first malignant primary breast cancer from 2000 to 2022 who received radiotherapy. Patients who died within two months of diagnosis were excluded. Standardized incidence ratios (SIRs) were calculated to compare observed to expected SPLC cases across racial and ethnic groups, stratified by latency intervals (2–11, 12–59, 60–119, and ≥120 months) and marital status. Racial categories included White, Black, Asian or Pacific Islander (API), and American Indian or Alaska Native (AI/AN); ethnicity was categorized as Hispanic or non-Hispanic. Five-year overall survival after SPLC was estimated using Kaplan–Meier analysis, and mean age at death was calculated by subgroup. Results: Among 558,493 radiotherapy-treated breast cancer patients, 6,674 developed SPLC (1.19%). Risk varied significantly by race (p < 0.05). Black survivors had a 21% excess risk (SIR 1.21, 95% CI: [1.12–1.31]), peaking 5–10 years post-treatment (SIR 1.44, [1 .26-1.63]) and remaining elevated beyond 10 years (SIR 1.24, [1.05-1.45]). API patients had a 23% overall excess risk (SIR 1.23, [1.11-1.36]), while AI/AN patients had the highest overall risk (SIR 1.82, [1.24-2.57]), particularly in the 12–59 month window (SIR 2.29, [1.25-3.84]) and ≥120 months (SIR 2.38, [1.19-4.26]). White survivors had no sustained increased risk (SIR 0.96, [0.93-0.98]), aside from a short-term rise in the first post-treatment year. Hispanic patients had consistently lower SPLC risk (overall SIR 0.72, [0.65-0.79]), while non-Hispanics had a transient early increase but an overall neutral risk (SIR 1.01, [0.99-1.04]). Marital status was protective: married individuals had a 12% lower SPLC incidence (SIR 0.88, 95% CI 0.85–0.91). Five-year overall survival after SPLC was 28.0%, with significant variation by race and ethnicity (p = 0.002). API (32.2%) and AI/AN (32.5%) patients had the highest survival, followed by White (28.0%) and Black patients (25.6%). Hispanic patients had the best outcomes, with 37.4% five-year survival and a mean age at death of 65.5 years, compared to 27.0% and 55.0 years for non-Hispanics (p = 0.005). Married patients had higher five-year survival (31.8%) and older mean age at death (64.3 years) compared to unmarried patients (25.0%, 48.6 years; p < 0.001). Conclusion: Radiation-associated SPLC risk and prognosis vary significantly by race, ethnicity, and marital status. Black and API survivors face sustained elevated risk; AI/AN survivors experience high early and long-term risk, while White and Hispanic survivors show no increased risk overall. Hispanic and married patients experience better survival after SPLC. These findings underscore the need for race and context aware survivorship counseling and suggest consideration of personalized lung cancer screening thresholds for breast cancer survivors receiving radiotherapy.